Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy

被引:53
作者
Thomas, Arun Z. [1 ]
Adibi, Mehrad [1 ]
Borregales, Leonardo D. [1 ]
Hoang, Ly N. [1 ]
Tamboli, Pheroze [2 ]
Jonasch, Eric [3 ]
Tannir, Nizar M. [3 ]
Matin, Surena F. [1 ]
Wood, Christopher G. [1 ]
Karam, Jose A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
关键词
kidney; carcinoma; renal cell; neoplasm recurrence; local; nephrectomy; lymph nodes; FOSSA RECURRENCE; INTERFERON-ALPHA; NATURAL-HISTORY; KIDNEY CANCER; RESECTION; OUTCOMES; THERAPY;
D O I
10.1016/j.juro.2015.02.2943
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Isolated local retroperitoneal recurrence after radical nephrectomy for renal cell carcinoma poses a therapeutic challenge. We investigated outcomes in patients with localized retroperitoneal recurrence treated with surgical resection. Materials and Methods: This was a retrospective, single institutional study of 102 patients with retroperitoneal recurrence treated with surgery from 1990 to 2014. Demographics, clinical and pathological features, location of retroperitoneal recurrence and perioperative complications are reported using descriptive statistics. We studied recurrence-free and cancer specific survival using univariate and multivariate analyses. Results: Median age at retroperitoneal recurrence diagnosis was 55 years (IQR 49-64). Cancer was pT3-4 in 62 patients (60.8%) and pN1 in 20 (19.6%). No patients had distant metastatic disease at retroperitoneal recurrence surgery. Median time from nephrectomy to retroperitoneal recurrence diagnosis was 19 months (IQR 5-38.8). The median size of the resected retroperitoneal recurrence was 4.5 cm (IQR 2.7-7). Median followup after recurrence surgery was 32 months (IQR 16-57). Metastatic progression was observed in 60 patients (58.8%) post-operatively. Neoadjuvant and salvage systemic therapy was administered in 46 (45.1%) and 48 patients (47.1%), respectively. On multivariate analysis pathological nodal stage at original nephrectomy and maximum diameter of retroperitoneal recurrence were identified as independent risk factors for cancer specific death. Conclusions: Clinicopathological factors at nephrectomy as well as retroperitoneal recurrence surgery are important prognosticators. Aggressive surgical resection offers potential cure in a substantial number of patients with retroperitoneal recurrence with acceptable complications and still has a dominant role in the management of isolated locally recurrent RCC.
引用
收藏
页码:316 / 322
页数:7
相关论文
共 30 条
[1]   Laparoscopic Adrenalectomy for Metachronous Metastases After Ipsilateral Nephrectomy for Renal-Cell Carcinoma [J].
Abel, E. Jason ;
Karam, Jose A. ;
Carrasco, Alonso ;
Matin, Surena F. .
JOURNAL OF ENDOUROLOGY, 2011, 25 (08) :1323-1327
[2]   Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy [J].
Boorjian, Stephen A. ;
Crispen, Paul L. ;
Lohse, Christine M. ;
Leibovich, Bradley C. ;
Blute, Michael L. .
JOURNAL OF UROLOGY, 2008, 180 (01) :99-103
[3]   Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival [J].
Bruno, J. James, II ;
Snyder, Mark E. ;
Motzer, Robert J. ;
Russo, Paul .
BJU INTERNATIONAL, 2006, 97 (05) :933-938
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   NATURAL-HISTORY OF METASTATIC RENAL CELL-CARCINOMA - COMPUTER-ANALYSIS [J].
DEKERNION, JB ;
RAMMING, KP ;
SMITH, RB .
JOURNAL OF UROLOGY, 1978, 120 (02) :148-152
[6]   Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era [J].
Di Lorenzo, Giuseppe ;
Autorino, Riccardo ;
Sternberg, Cora N. .
EUROPEAN UROLOGY, 2009, 56 (06) :959-971
[7]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[8]  
Edge SB, 2010, CANC STAGING HDB AJC, p[xix, 718]
[9]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[10]   Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].
Escudier, Bernard ;
Bellmunt, Joaquim ;
Negrier, Sylvie ;
Bajetta, Emilio ;
Melichar, Bohuslav ;
Bracarda, Sergio ;
Ravaud, Alain ;
Golding, Sophie ;
Jethwa, Sangeeta ;
Sneller, Vesna .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150